Pulmotect’s lead product, PUL-042, is a clinical stage inhaled therapeutic that stimulates the innate immune system in the lungs to provide immediate and effective protection against viral, bacterial and fungal pathogens.

Phase I/2a clinical trials demonstrated that PUL-042 was well tolerated in healthy individuals and subjects with COPD. Two exploratory phase 2 trials demonstrated anti-viral activity and proof of clinical concept. Phase 2 studies are planned to assess the effectiveness of PUL-042 in preventing respiratory complications such as pneumonia and on improving outcomes in immunocompromised cancer patients. Other at risk populations that could benefit from PUL-042 include COPD, asthma and seasonal infections.